HOSPIRA - Key Persons

Job Titles:

• Member of the People in Executive Leadership Team
• Chief Business Innovation Officer, Executive Vice President

Aamir Malik is Executive Vice President, Chief Business Innovation Officer, responsible for the company's strategy, business development, commercial development, portfolio management, pipeline prioritization, and formation of new business ventures. Prior to joining Pfizer, Aamir was the Managing Partner of McKinsey & Company's United States operations and previously led the firm's Global Pharmaceutical and Medical Products Practice. In his 25 years at McKinsey, Aamir developed innovative growth strategies, guided mergers and acquisitions, and implemented high-impact programs to improve patients' lives and transform performance for life science companies. He has advised many Boards, CEOs, and top management teams in the life science space. Aamir earned a Bachelor of Science in finance from Indiana University and currently serves on the University's Kelly School of Business Dean's Council. He is an active advocate for bettering the lives of people with food allergies and has lived and worked globally, including in the United States, Europe, Asia, Latin America, and Africa.

Job Titles:

• Member of the People in Executive Leadership Team
• Chief Commercial Officer and President of the Global Biopharmaceuticals Business
• Chief Commercial Officer, President, Global Biopharmaceuticals Business

Angela Hwang is the Chief Commercial Officer and President of the Global Biopharmaceuticals Business at Pfizer and a member of its Executive Leadership Team. She and her organization, comprised of over 26,000 colleagues, are responsible for delivering all 600 of Pfizer's medicines and vaccines to patients in 185 countries. In 2022, more than 1.3 billion people received a Pfizer therapy that protected and improved their health. Under Angela's leadership, Pfizer Biopharma generated $100 billion in 2022 revenues. Pfizer's Biopharma business addresses major global health priorities, including cancer, COVID-19, infectious diseases, inflammation & immunology, rare diseases, cardiovascular/metabolic disorders, and preventative care with vaccines. But Angela's work goes beyond making medicines available. She is equally focused on creating and expanding collaborations with health insurers, governments, policymakers, and global health stakeholders around the world to come up with new and better ways to meet health challenges and make medicines accessible and affordable for all. In 2020, Angela and Pfizer's Biopharma team launched the world's first COVID-19 vaccine and, one year later, the first oral antiviral treatment. Though vaccines often take many years to develop distribute, Angela and her team-inspired by a relentless focus on helping patients-made the impossible possible. Angela's commitment to health equity has deep roots. Her experience growing up as an Asian girl in South Africa during the apartheid era shaped her worldview. It helps explain why, after 27 years at Pfizer, she continues to find purpose and common cause with her Pfizer colleagues to bring more breakthroughs to patients, no matter who they are or where they live. Under Angela's leadership, Pfizer launched An Accord for a Healthier World, a first-of-its-kind initiative to enable sustained, equitable access to all of Pfizer's medicines and vaccines in 45 lower-income countries. The Accord has the potential to improve the health of 1.2 billion people and transform the healthcare ecosystem in those countries. Beyond her work at Pfizer, Angela serves on the Board of Directors of UPS, the European Federation of Pharmaceutical Industries and Associations, the U.S. China Business Council, Cornell's Johnson Graduate School of Management Advisory Council, and the Pfizer Foundation, which uses the power of philanthropy to improve global health. Angela is consistently ranked among the world's top leaders in healthcare and business by publications including Crain's, Business Insider, Forbes, and Fortune, which placed her in the top 20 Most Powerful Women in Business three years in a row. Angela is also an honoree of A100, which recognizes the most impactful Asian American and Pacific Islander (AAPI) leaders. In 2021, she received the President's Award from the National Diversity Council for championing diversity, equity, and inclusion. Cornell University named Angela a Robert S. Hatfield Economic Fellow in 2022. In 2023, she was recognized as a Ascend A-list Honoree for her professional achievements as an Asian American leader. Angela received her Bachelor of Science in Microbiology and Biochemistry from the University of Cape Town and her MBA from Cornell. Angela and her husband are proud parents of a teenage daughter and son. Angela is a fierce advocate for women's leadership and sustainable global health equity.

Job Titles:

• Vice President, Metabolic Research

Job Titles:

• Principal Scientist, Oncology Medicinal Chemistry

Job Titles:

• Member of the People in Executive Leadership Team
• Chief Oncology Research & Development Officer, Executive Vice President

As Chief Oncology Research & Development (ORD) Officer and Executive Vice President, Chris Boshoff leads Pfizer's Oncology research and development organization from drug discovery to approval (including Oncology research) and through early and late phase clinical development. Prior to Pfizer, Chris was the founding Director of the University College London (UCL) Cancer Institute, London, U.K. He earned a PhD from the Institute of Cancer Research in London and trained as a medical oncologist at the Royal Marsden and Royal Free Hospitals in London. He is a Fellow of the Royal College of Physicians and an elected Fellow of the U.K. Academy of Medical Sciences. Chris was appointed an Adjunct Professor at Yale University School of Medicine in 2014, and as a clinician scientist has published more than 150 articles, many highly cited, on cancer biology, tumor virology, and experimental cancer medicine. At Pfizer, Chris and his team have delivered numerous cancer medicines from Phase 1 to global approvals. This includes overseeing many U.S. Food and Drug Administration breakthrough therapy and European Medicines Agency Priority Medicines (PRIME) designations and delivering various Companion Diagnostics for Pfizer's precision medicines-all with the goal of delivering breakthrough medicines for patients with cancer.

Job Titles:

• Senior Director, Biology and Nice Site Lead

Job Titles:

• Chief Financial Officer
• Executive Vice President
• Member of the People in Executive Leadership Team

Job Titles:

• Executive Vice President
• General Counsel
• Member of the People in Executive Leadership Team

Job Titles:

• Chairman
• Chief Executive Officer
• Member of the People in Executive Leadership Team
• Chairman of the Pfizer Foundation
• Doctor of Veterinary Medicine

Age: 61 years As Chairman and Chief Executive Officer, Albert Bourla leads Pfizer in its purpose, "Breakthroughs that change patients' lives," with a focus on driving the scientific and commercial innovation needed to have a transformational impact on human health. During his more than 30 years at Pfizer, Albert has built a diverse and successful career, holding several senior positions across a range of markets and disciplines. The global nature of his work- having lived and worked in nine different cities and led teams across five continents-has informed his understanding of the needs of patients and healthcare systems around the world and deepened his commitment to helping ensure equitable access to medicines and vaccines. When he took the reins as CEO in January 2019, Albert accelerated Pfizer's transformation to become a more science-driven, innovative company-divesting its non-science-based businesses and dramatically increasing its R&D and digital innovation budgets. To create a culture in which the company's people and science could thrive, Albert and his leadership team established Pfizer's Purpose Blueprint, which included four core values: courage, excellence, equity, and joy. A powerful example of Pfizer's capabilities and culture was seen in the company's response to the COVID-19 pandemic. Refusing to accept public funding and instead investing more than $2 billion dollars at-risk, Albert inspired colleagues to deliver a safe and effective vaccine in just eight months -a process that typically take 8-10 years-without compromising quality or integrity. A year later, continuing to move at the speed of science, Pfizer delivered the first FDA-authorized oral antiviral treatment for COVID-19 by implementing the same sense of urgency and new ways of working that had made the vaccine program so successful. The company is now applying many of these "lightspeed" principles to projects across a wide range of therapeutic areas, including cancer, cardiovascular disease, inflammatory conditions, and more. Albert wrote about the company's experience developing a COVID-19 vaccine in his book, Moonshot: Inside Pfizer's Nine-Month Race to Make the Impossible Possible, which was a Bronze Medalist in the 2023 Axiom Awards and a Finalist for the National Jewish Book Awards. The book also appeared on the Wall Street Journal Bestseller list for four weeks and was selected by the Next Big Idea Book Club. Under Albert's leadership, Pfizer also has further strengthened its commitment to Environmental, Social and Governance (ESG) principles. This includes issuing the biopharmaceutical industry's first Sustainability Bond addressing capital investments in both environmental and social initiatives; launching the company's first ESG report; and completing an extensive priority issue assessment to confirm where and how Pfizer can have the greatest long-term impact. Albert is a Doctor of Veterinary Medicine and holds a Ph.D. in the Biotechnology of Reproduction from the Veterinary School of Aristotle University. He has received honorary doctorates from the American College of Greece, the University of Patras, Touro University, The Technion-Israel Institute of Technology, and Aristotle University, as well as an honorary degree from Babson College. In 2022, Albert received the Golden Cross Order of the Redeemer, conferred by the President of Greece; the Order of Boyacá, conferred by the President of Colombia; and the Order of the Independence from the First Degree, conferred by His Majesty King Abdullah II of Jordan. In the same year, he was named the 2022 Genesis Prize Laureate in recognition of his leadership during the COVID-19 pandemic and received the Courage Against Hate Award from the Anti-Defamation League. He also received the 2022 Eisenhower Global Citizenship Award from the Business Council for International Understanding, the Distinguished Leadership Award, and the Peter G. Peterson Business Statesmanship Award from the Committee for Economic Development, the Gold Medal from Americas Society, the Bower Award in Business Leadership from The Franklin Institute, the Double Helix Award from Cold Spring Harbor Laboratory, the Humanitarian Award from the Simon Wiesenthal Center, and the Manufacturer of the Year from the National Association of Manufacturers' Leadership Council. In 2021, he was named CEO of the Year by CNN Business, included in Insider Magazine's Most Transformative CEOs list and inducted into the Crain's New York Business 2021 Hall of Fame. That same year, he received the Appeal of Conscience Award in recognition of his extraordinary leadership in service of the global community and The Atlantic Council's Distinguished Business Leadership Award for his and Pfizer's work on the COVID-19 vaccine. He also was recognized with the Roy Vagelos Award from the Prix Galien Foundation, the Academy of Achievement Award in Science from AHEPA, the Golden Medal of Institution from Hellenic Open University, the David Rockefeller Award from the Museum of Modern Art, the Theodor Herzl Award from the World Jewish Congress, the Sparkle of Hope Award from Community Hope, and the Father of the Year Award from the National Father's Day Council. In 2020, he received the Meridian Global Leadership Award. Albert is chairman of The Pfizer Foundation and Co-Chair of the Board of Directors for the Partnership for New York City. He is President of the International Federation of Pharmaceutical Manufacturers & Associations, a director on multiple boards-Pfizer Inc., PhRMA and Catalyst-and a trustee of the United States Council for International Business. In addition, Albert is a member of the Council on Foreign Relations, the Business Roundtable, the Business Council, and the New York City Mayor's Corporate Council. Albert can be found on Twitter at @AlbertBourla and on LinkedIn.

Emile Pfizer was the last member of the Pfizer/Erhart family to be actively involved with the company. He was president from 1906 to 1941.

Job Titles:

• Associate Research Fellow, Hit Discovery and Lead Profiling

Job Titles:

• Chairman of the Board

Job Titles:

• Health Care Professionals

Job Titles:

• CEO
• Chairman

Hank McKinnell, CEO and Chairman of Pfizer, announces the Global Health Fellows program at the World AIDS Conference in Barcelona - a call to action for Pfizer colleagues to volunteer in developing countries for up to six months on HIV/AIDS projects. In 2003, the first eighteen Global Health Fellows are sent into the field.

Job Titles:

• Chief Executive Officer

Age: 58 years Chairman and Chief Executive Officer of The Coca-Cola Company, a total beverage company with products sold in more than 200 countries and territories. He was appointed Chairman of the Board in 2019 and CEO in 2017. Prior to his appointment as CEO in 2017, he held various leadership roles at The Coca-Cola Company, including President and Chief Operating Officer from 2015 to 2017, President of the Europe Group, President of the Northwest Europe and Nordics business unit and President of the Mexico division. Director of US - China Business Council and Catalyst.

Job Titles:

• Assistant

Job Titles:

• CEO
• Chairman

Jeff Kindler, Chairman and CEO of Pfizer, announces the next step in the company's evolution and outlines the company's plan to establish smaller operating units designed to enhance innovation and accountability, while drawing upon the advantages of Pfizer's scale and resources. These customer-focused business units allow Pfizer to better anticipate and respond to customers' and patients' needs, as well responds to changes in the marketplace.

Job Titles:

• Chief Scientific Officer

Job Titles:

• Senior Director, Oncology Medicinal Chemistry Synthesis and Analytical Group

Job Titles:

• Vice President and Clinical Portfolio Leader

Job Titles:

• President and Chief Executive Officer Chas. Pfizer & Co., Inc. 1966

John J. Powers, Jr.,is named president and CEO. John McKeen, whom he succeeds, remains chairman of the board, a position he holds until 1968, when Powers assumes full leadership of the company.

Job Titles:

• CEO of the University of Miami

Age: 66 years Served as the CEO of Deloitte LLP, a global provider of professional services, from 2011 until his retirement in 2014. During his 36-year tenure with Deloitte, served in various leadership roles, including Deputy Managing Partner, Southeast Region, Audit Managing Partner and U.S. Managing Partner and Chief Operating Officer. Since 2022, Mr. Echevarria has served as CEO of the University of Miami (UM), and served as Trustee of UM since 2011. Serves as Chair Emeritus of former President Obama's My Brother's Keeper Alliance and as an advisor to the Obama Foundation. Chairman of the Board of The Bank of New York Mellon Corporation. Director of Unum Group, a provider of financial protection benefits. Former Director of Xerox Holdings Corporation (2017-2023). Former Member of the President's Export Council and former member of the Presidential Commission on Election Administration.

Job Titles:

• Executive Director, Patient Advocacy Lead

Job Titles:

• Executive Director, Metabolism

Job Titles:

• Member of the People in Executive Leadership Team
• Chief Digital and Technology Officer, Executive Vice President

Job Titles:

• SVP & Chief Medical Officer, Pfizer Vaccines

Job Titles:

• Professor of Molecular Immunology

Job Titles:

• Member of the People in Executive Leadership Team
• Chief Scientific Officer, President, Pfizer Research & Development

Job Titles:

• Member of the People in Executive Leadership Team
• Chief Global Supply Officer, Executive Vice President

Job Titles:

• Senior Director

Job Titles:

• Associate Research Fellow and Group Leader, Chemical Development Active Pharmaceutical Ingredients

Job Titles:

• Member of the People in Executive Leadership Team
• Chief People Experience Officer, Executive Vice President

Job Titles:

• Member of the People in Executive Leadership Team
• Chief Compliance, Quality and Risk Officer, Executive Vice President

Job Titles:

• Senior Research Fellow, Pharmaceutical Sciences

Job Titles:

• Doctor

Doctor Richard Pasternack develops a fermentation-free method for producing ascorbic acid, vitamin C. After building a new plant and initiating a 24-hour-a-day, seven-day-a-week production schedule, Pfizer becomes the world's leading producer of vitamin C.

Age: 63 years Founder, Managing Partner of GenNx360 Capital Partners, a private equity firm focused on investing in industrial and business services companies in the U.S. middle market since 2006. Prior to launching GenNx360 Capital Partners, Mr. Blaylock founded and managed Blaylock & Company, an investment banking firm. He also held senior management positions at UBS, PaineWebber Group and Citicorp.

Job Titles:

• Member of the People in Executive Leadership Team
• Chief Corporate Affairs Officer, Executive Vice President

Age: 51 years Partner, New Enterprise Associates, Inc.'s Healthcare Investment Team and Resident Fellow of the American Enterprise Institute since 2019. Served as the 23rd Commissioner of the FDA from 2017 to 2019. Prior to serving as Commissioner of the FDA, Dr. Gottlieb held several roles in the public and private sectors, including serving as a Venture Partner to New Enterprise Associates, Inc. from 2007 to 2017.

Job Titles:

• Lead Independent Director

Age: 60 years Chairman since 2017 and Chief Executive Officer since 2007 of Adobe, one of the largest and most diversified software companies in the world. President of Adobe until December 2021. Prior to his appointment as CEO, he held various leadership roles at Adobe, including President and Chief Operating Officer, Executive Vice President of Worldwide Products, and Senior Vice President of Worldwide Product Development.

Age: 66 years Retired Vice Chairman, Goldman Sachs, since 2007. During her 21-year tenure with Goldman Sachs, she served in various leadership roles, including Chair of the Global Markets Institute, Head of Global Research, and Head of Global Health Care.

Job Titles:

• Vice President, Discovery

Job Titles:

• Science

Job Titles:

• Senior Vice President of Pfizer Vaccine Clinical Research and Development

Job Titles:

• Senior Vice President and Chief Scientific Officer, Internal Medicine Research Unit

Job Titles:

• Becomes Chairman of the Board

William C. Steere, Jr. announces his retirement as CEO on January 1, 2001, and steps down as Chairman of the Board in April, following the company's annual meeting. Henry A. McKinnell, Jr., Ph.D. succeeds William C. Steere, Jr. as Chairman and Chief Executive Officer. William C. Steere, Jr., is appointed President. A year later, he is also named Chief Executive Officer.

William H. Erhart, son of Charles Erhart, one of the two original founders. He became vice president of the company in 1900 and served as Chairman of the Board from 1929 to 1940.